First Cystic Fibrosis Drugs To Target Underlying Genetic Defect Are In Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The first cystic fibrosis drugs to mitigate the ion transport defect underlying the disease are in Phase II, with the support of the Cystic Fibrosis Foundation’s extensive therapeutics development program.
You may also be interested in...
Breath Of Fresh Air For Cystic Fibrosis Drug Pipeline
The outlook for cystic fibrosis drug development now is "a very different story than even five years ago," according to Cystic Fibrosis Foundation President Robert Beall.
Inspire Denufosol Phase II Cystic Fibrosis Data Support Early Use, Firm Says
Inspire is hoping to expedite moving its cystic fibrosis therapy, INS-37217, into Phase III following better-than-expected Phase II results.
Inspire Denufosol Phase II Cystic Fibrosis Data Support Early Use, Firm Says
Inspire is hoping to expedite moving its cystic fibrosis therapy, INS-37217, into Phase III following better-than-expected Phase II results.